QuantRX Biomedical Corporation
100 South Main Street
Suite 300
Doylestown,
PA 18901
Phone: 267-880-1595
Fax: 267-880-1596
Web Site: http://www.quantrx.com
| QuantRx Biomedical Corporation, a diagnostics company, focuses on the development and commercialization of diagnostic products based on its patented technology platforms for the worldwide healthcare industry. The company's technology portfolio includes RapidSense point-of-care testing products based on its core intellectual property related to lateral flow techniques for the consumer and healthcare professional markets; and PAD technology for over-the-counter applications, and the diagnosis and treatment of women's health concerns and other medical needs. It also focuses on investing in genome-based diagnostic chips for the laboratory and healthcare professional markets; and molecular imaging agents for positron emission tomography and fluorescence imaging, with initial application in cardiovascular disease, addressing unmet medical needs by providing clinicians with tools for early discovery and assessment. QuantRx has a joint venture with NuRx Pharmaceuticals, Inc. to launch point-of-care products. The company was formerly known as A-Fem Medical Corporation and changed its name to QuantRx Biomedical Corporation in November 2006. QuantRx was incorporated in 1986 and is headquartered in Doylestown, Pennsylvania. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Mr. Walter Witoshkin , 65
Chairman, Chief Exec. Officer and Pres
|
N/A
|
N/A |
Mr. Sasha Afanassiev CPA, 42
Chief Financial Officer, VP of Fin. and Treasurer
|
$
150.00K |
N/A |
Dr. William H. Fleming Ph.D., 62
Chief Scientific Officer, Sec., Director, Chairman of Audit Committee and Pres of Diagnostics
|
N/A
|
N/A |
Mr. James R. Wilson , 60
Director of Bus. Devel.
|
N/A
|
N/A |
Mr. Martin Harvey , 68
Controller
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
0.02 (5.41%) 
Profile
